Market Overview

Top 4 Mid-Cap Stocks In The Drugs-Generic Industry With The Highest ROA

Related AKRX
Is Akorn, Inc. An Easy Buy This Week?
5 Drug Companies Profiting From Generics
Merck Sells Japan Eye-Treatment Rights (Fox Business)
Related SLXP
UCERIS 2mg Rectal Foam For The Induction Of Remission Of Mild-To-Moderate Distal Ulcerative Colitis Granted Tentative Approval By FDA
Credit Suisse Sees Downside In Shares Of Salix Pharmaceuticals, Ltd.

Below are the top mid-cap drugs-generic stocks on the NYSE and the NASDAQ in terms of return on assets.

The trailing-twelve-month return on assets at Akorn (NASDAQ: AKRX) is 13.00%. Akorn's EPS for the same period is $0.46.

The trailing-twelve-month return on assets at Salix Pharmaceuticals (NASDAQ: SLXP) is 6.40%. Salix's revenue for the same period is $1.12 billion.

The trailing-twelve-month return on assets at Mallinckrodt plc (NYSE: MNK) is 2.50%. Mallinckrodt's operating margin for the same period is 9.20%.

The trailing-twelve-month return on assets at Hospira (NYSE: HSP) is 1.00%. Hospira's PEG ratio is 5.78.

Posted-In: Drugs-Generic Industry Mid-Cap ROATrading Ideas

 

Related Articles (AKRX + HSP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters